Mitsukuni Suenaga

10PUBLICATIONS
20CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 12, 2026
Clinical Impact of Baseline ctDNA RAS/BRAF Mutations on Conversion Surgery and Outcomes in First-Line Anti-EGFR Therapy for Advanced Colorectal Cancer.

|Aug 29, 2024
Exploratory Study Identifies Matrix Metalloproteinase-14 and -9 as Potential Biomarkers of Regorafenib Efficacy in Metastatic Colorectal Cancer.

Mitsukuni Suenaga, Tetsuo Mashima, Naomi Kawata

|Feb 05, 2021
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.

Mitsukuni Suenaga, Marta Schirripa, Shu Cao

|Sep 24, 2020
A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.

Yuji Miyamoto, Marta Schirripa, Mitsukuni Suenaga

|Sep 13, 2020
Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer.

Mitsukuni Suenaga, Tetsuo Mashima, Naomi Kawata

|Jul 08, 2020
Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial.

Mitsukuni Suenaga, Marta Schirripa, Shu Cao

Pageof 2

Frequent Collaborators

3 joint publications

Yuji Miyamoto

2 joint publications

Sara Lonardi

1 joint publications

Sebastian Stintzing

1 joint publications

Satoshi Okazaki